Skip to content
Open access

Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency

Sep 2026 · Nature Genetics · Vol 58, pp. 2590 - 2604 · 0 citations · 89 references
Medicine

Abstract

Medulloblastoma is a biologically heterogeneous childhood cerebellar tumor harboring frequent chromatin-modifying gene alterations. How these alterations promote transcriptional programs governing malignancy remains poorly defined. To address this knowledge gap, we evaluated chromatin states across medulloblastoma subgroups by multi-modal integration of histone modifications with mutational, DNA methylation and transcriptomic profiles. A bivalent/poised enhancer (EnhBiv) state was specifically enriched at the promoters of neurodevelopmental genes in Group 3/4 medulloblastoma. Integrative bioinformatics coupled with chromatin occupancy studies identified aberrant KDM2B binding at EnhBiv-enriched promoters. CRISPR-mediated knockout or acute protein degradation of KDM2B selectively suppressed the growth of medulloblastoma models in vitro and in vivo. Mechanistically, KDM2B promotes sequential recruitment of Polycomb repressive complexes (PRC1/PRC2) and EnhBiv chromatin, thereby repressing neuronal differentiation programs. Collectively, we provide foundational insights into an epigenetic basis of medulloblastoma, nominating KDM2B as a selective dependency in high-risk subgroups that warrants consideration as a candidate therapeutic target. Epigenomic analyses of medulloblastoma identify a bivalent/poised enhancer (EnhBiv) chromatin signature enriched for KDM2B binding in Group 3 and Group 4 tumors. Functional work suggests a selective dependency of these subtypes on KDM2B.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.